Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice

Li,Wu; Li,Min; Deng,Guangcun; Zhao,Liping; Liu,Xiaoming; Wang,Yujiong

doi:10.3892/mmr.2015.3770

Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice

Authors:
- Wu Li
- Min Li
- Guangcun Deng
- Liping Zhao
- Xiaoming Liu
- Yujiong Wang
View Affiliations

Affiliations: Key Laboratory of Ministry of Education for Conservation and Utilization of Special Biological Resources in Western China, College of Life Science, Ningxia University, Ningxia 750021, P.R. China, State Key Laboratory of Microbial Metabolism, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai 200240, P.R. China
Published online on: May 12, 2015 https://doi.org/10.3892/mmr.2015.3770
Pages: 3073-3080

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tuberculosis (TB) remains to be a prevalent health issue worldwide. At present, Mycobacterium bovis Bacillus Calmette Guerin (BCG) is the singular anti‑TB vaccine available for the prevention of disease in humans; however, this vaccine only provides limited protection against Mycobacterium tuberculosis (Mtb) infection. Therefore, the development of alternative vaccines and strategies for increasing the efficacy of vaccination against TB are urgently required. The present study aimed to evaluate the ability of a recombinant adenoviral vector (Ad5‑CEAB) co‑expressing 10‑kDa culture filtrate protein, 6‑kDa early‑secreted antigenic target, antigen 85 (Ag85)A and Ag85B of Mtb to boost immune responses following primary vaccination with BCG in mice. The mice were first subcutaneously primed with BCG and boosted with two doses of Ad5-CEAB via an intranasal route. The immunological effects of Ad5-CEAB boosted mice primed with BCG were then evaluated using a series of immunological indexes. The results demonstrated that the prime‑boost strategy induced a potent antigen‑specific immune response, which was primarily characterized by an enhanced T cell response and increased production of cytokines, including interferon‑γ, tumor necrosis factor‑α and interleukin‑2, in mice. In addition, this vaccination strategy was demonstrated to have an elevated humoral response with increased concentrations of antigen‑specific bronchoalveolar lavage secretory immunoglobulin (Ig)A and serum IgG in mice compared with those primed with BCG alone. These data suggested that the regimen of subcutaneous BCG prime and mucosal Ad5‑CEAB boost was a novel strategy for inducing a broad range of antigen‑specific immune responses to Mtb antigens in vivo, which may provide a promising strategy for further development of adenoviral-based vaccine against Mtb infection.

View Figures

View References

1	World Health Organization (WHO): Global Tuberculosis Report 2012. WHO; Geneva, Switzerland: pp. 3062012
2	Churchyard GJ, Chaisson RE, Maartens G and Getahun H: Tuberculosis preventive therapy: An underutilised strategy to reduce individual risk of TB and contribute to TB control. S Afr Med J. 104:339–343. 2014. View Article : Google Scholar : PubMed/NCBI
3	Muwonge A, Malama S, Johansen TB, et al: Molecular epidemiology, drug susceptibility and economic aspects of tuberculosis in Mubende district, Uganda. PLoS One. 8:e647452013. View Article : Google Scholar : PubMed/NCBI
4	Awasthi S and Moin S: Effectiveness of BCG vaccination against tuberculous meningitis. Indian Pediatr. 36:455–460. 1999.
5	Nuttall JJ, Davies MA, Hussey GD and Eley BS: Bacillus Calmette-Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy. Int J Infect Dis. 12:e99–e105. 2008. View Article : Google Scholar : PubMed/NCBI
6	Bolger T, O’Connell M, Menon A and Butler K: Complications associated with the bacille Calmette-Guérin vaccination in Ireland. Arch Dis Child. 91:594–597. 2006. View Article : Google Scholar : PubMed/NCBI
7	McShane H and Hill A: Prime-boost immunisation strategies for tuberculosis. Microbes Infect. 7:962–967. 2005. View Article : Google Scholar : PubMed/NCBI
8	Dean G, Whelan A, Clifford D, et al: Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines. Vaccine. 32:1304–1310. 2014. View Article : Google Scholar
9	Hoft DF, Blazevic A, Stanley J, et al: A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine. 30:2098–2108. 2012. View Article : Google Scholar : PubMed/NCBI
10	Perez de Val B, Villarreal-Ramos B, Nofrarías M, et al: Goats primed with Mycobacterium bovis BCG and boosted with a recombinant adenovirus expressing Ag85A show enhanced protection against tuberculosis. Clin Vaccine Immunol. 19:1339–1347. 2012. View Article : Google Scholar : PubMed/NCBI
11	Dou J, Wang Y, Yu F, et al: Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting. Int J Immunogenet. 39:183–190. 2012. View Article : Google Scholar
12	Cervantes-Villagrana AR, Hernández-Pando R, Biragyn A, et al: Prime-boost BCG vaccination with DNA vaccines based in β-defensin-2 and mycobacterial antigens ESAT6 or Ag85B improve protection in a tuberculosis experimental model. Vaccine. 31:676–684. 2013. View Article : Google Scholar
13	Xing Z and Lichty BD: Use of recombinant virus-vectored tuberculosis vaccines for respiratory mucosal immunization. Tuberculosis. 86:211–217. 2006. View Article : Google Scholar : PubMed/NCBI
14	Lasaro MO and Ertl HC: New insights on adenovirus as vaccine vectors. Mol Ther. 17:1333–1339. 2009. View Article : Google Scholar : PubMed/NCBI
15	Wang J, Thorson L, Stokes RW, et al: Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol. 173:6357–6365. 2004. View Article : Google Scholar : PubMed/NCBI
16	Li W, Deng G, Li M, Liu X and Wang Y: Roles of mucosal immunity against Mycobacterium tuberculosis infection. Tuberc Res Treat. 2012. View Article : Google Scholar : PubMed/NCBI
17	Cripps AW, Kyd JM and Foxwell AR: Vaccines and mucosal immunisation. Vaccine. 19:2513–2515. 2001. View Article : Google Scholar : PubMed/NCBI
18	Li W, Deng G, Li M, et al: A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice. Mol Immunol. 62:86–95. 2014. View Article : Google Scholar : PubMed/NCBI
19	Zhang H, Peng P, Miao S, et al: Recombinant Mycobacterium smegmatis expressing an ESAT6-CFP10 fusion protein induces anti-mycobacterial immune responses and protects against Mycobacterium tuberculosis challenge in mice. Scand J Immunol. 72:349–357. 2010. View Article : Google Scholar : PubMed/NCBI
20	Liang Y, Wu X, Zhang J, et al: Immunogenicity and therapeutic effects of Ag85A/B chimeric DNA vaccine in mice infected with Mycobacterium tuberculosis. FEMS Immunol Med Microbiol. 66:419–426. 2012. View Article : Google Scholar : PubMed/NCBI
21	Pydi SS, Bandaru AR, Venkatasubramanian S, et al: Vaccine for tuberculosis: up-regulation of IL-15 by Ag85A and not by ESAT-6. Tuberculosis (Edinb). 91:136–139. 2011. View Article : Google Scholar
22	Sibley L, Reljic R, Radford DS, et al: Recombinant Bacillus subtilis spores expressing MPT64 evaluated as a vaccine against tuberculosis in the murine model. FEMS Microbiol Lett. 358:170–179. 2014. View Article : Google Scholar : PubMed/NCBI
23	Shi S, Yu L, Sun D, Liu J and Hickey AJ: Rational design of multiple TB antigens TB10.4 and TB10.4-Ag85B as subunit vaccine candidates against Mycobacterium tuberculosis. Pharm Res. 27:224–234. 2010. View Article : Google Scholar
24	Berthet FX, Rasmussen PB, Rosenkrands I, Andersen P and Gicquel B: A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). Microbiology. 144(Pt 11): 3195–3203. 1998. View Article : Google Scholar : PubMed/NCBI
25	Gordon SV, Brosch R, Billault A, Garnier T, Eiglmeier K and Cole ST: Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol. 32:643–655. 1999. View Article : Google Scholar : PubMed/NCBI
26	Behr MA, Wilson MA, Gill WP, et al: Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science. 284:1520–1523. 1999. View Article : Google Scholar : PubMed/NCBI
27	Lewis KN, Liao R, Guinn KM, et al: Deletion of RD1 from Mycobacterium tuberculosis mimics Bacille Calmette-Guerin attenuation. J Infect Dis. 187:117–123. 2003. View Article : Google Scholar : PubMed/NCBI
28	Pym AS, Brodin P, Brosch R, Huerre M and Cole ST: Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol. 46:709–717. 2002. View Article : Google Scholar : PubMed/NCBI
29	You Q, Wu Y, Jiang D, et al: Immune responses induced by heterologous boosting of recombinant bacillus Calmette-Guerin with Ag85B-ESAT6 fusion protein in levamisole-based adjuvant. Immunol Invest. 41:412–428. 2012. View Article : Google Scholar : PubMed/NCBI
30	Yuan W, Dong N, Zhang L, et al: Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice. Vaccine. 30:2490–2497. 2012. View Article : Google Scholar
31	Esparza-González SC, Troy A, Troudt J, et al: Recombinant adenovirus delivery of calreticulin-ESAT-6 produces an antigen-specific immune response but no protection against a Mycobacterium tuberculosis challenge. Scand J Immunol. 75:259–265. 2012. View Article : Google Scholar
32	Lin CW, Su IJ, Chang JR, Chen YY, Lu JJ and Dou HY: Recombinant BCG coexpressing Ag85B, CFP10 and interleukin-12 induces multifunctional Th1 and memory T cells in mice. APMIS. 120:72–82. 2012. View Article : Google Scholar
33	Betts G, Poyntz H, Stylianou E, et al: Optimising immunoge-nicity with viral vectors: mixing MVA and HAdV-5 expressing the mycobacterial antigen Ag85A in a single injection. PLoS One. 7:e504472012. View Article : Google Scholar
34	Dietrich J, Andersen C, Rappuoli R, Doherty TM, Jensen CG and Andersen P: Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity. J Immunol. 177:6353–6360. 2006. View Article : Google Scholar : PubMed/NCBI
35	Dou J, Tang Q, Yu F, et al: Investigation of immunogenic effect of the BCG priming and Ag85A-GM-CSF boosting in Balb/c mice model. Immunobiology. 215:133–142. 2010. View Article : Google Scholar
36	Lu D, Garcia-Contreras L, Muttil P, et al: Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. AAPS J. 12:338–347. 2010. View Article : Google Scholar : PubMed/NCBI
37	Wakeham J, Wang J, Magram J, et al: Lack of both types 1 and 2 cytokines, tissue inflammatory responses and immune protection during pulmonary infection by Mycobacterium bovis bacille Calmette-Guerin in IL-12-deficient mice. J Immunol. 160:6101–6111. 1998.PubMed/NCBI
38	Williams A, Reljic R, Naylor I, et al: Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs. Immunology. 111:328–333. 2004. View Article : Google Scholar : PubMed/NCBI
39	Borrero R, García Mde L, Canet L, et al: Evaluation of the humoral immune response and cross reactivity against Mycobacterium tuberculosis of mice immunized with liposomes containing glycolipids of Mycobacterium smegmatis. BMC Immunol. 14(Suppl 1): 132013. View Article : Google Scholar
40	Rodrigues LC, Pereira SM, Cunha SS, et al: Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet. 366:1290–1295. 2005. View Article : Google Scholar : PubMed/NCBI
41	Dantas OM, Ximenes RA, de Albuquerque Mde F, et al: A case-control study of protection against tuberculosis by BCG revaccination in Recife, Brazil. Int J Tuberc Lung Dis. 10:536–541. 2006.PubMed/NCBI
42	Basaraba RJ, Izzo AA, Brandt L and Orme IM: Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine. 24:280–286. 2006. View Article : Google Scholar
43	Buddle B, Wedlock D, Parlane N, et al: Revaccination of neonatal calves with Mycobacterium bovis BCG reduces the level of protection against bovine tuberculosis induced by a single vaccination. Infect Immun. 71:6411–6419. 2003. View Article : Google Scholar : PubMed/NCBI
44	Seder RA and Hill AV: Vaccines against intracellular infections requiring cellular immunity. Nature. 406:793–798. 2000. View Article : Google Scholar : PubMed/NCBI
45	Flynn JL and Chan J: Immunology of tuberculosis. Annu Rev Immunol. 19:93–129. 2001. View Article : Google Scholar : PubMed/NCBI
46	Woodworth JS, Wu Y and Behar SM: Mycobacterium tuberculosis-specific CD8+T cells require perforin to kill target cells and provide protection in vivo. J Immunol. 181:8595–8603. 2008. View Article : Google Scholar : PubMed/NCBI
47	Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP and Glimcher LH: Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science. 295:338–342. 2002. View Article : Google Scholar : PubMed/NCBI
48	Sharma M, Sharma S, Roy S, Varma S and Bose M: Pulmonary epithelial cells are a source of interferon-γ in response to Mycobacterium tuberculosis infection. Immunol Cell Biol. 85:229–237. 2007.PubMed/NCBI
49	Bean AG, Roach DR, Briscoe H, et al: Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuber- culosis infection, which is not compensated for by lymphotoxin. J Immunol. 162:3504–3511. 1999.PubMed/NCBI
50	Mazanec MB, Nedrud JG, Kaetzel CS and Lamm ME: A three-tiered view of the role of IgA in mucosal defense. Immunol Today. 14:430–435. 1993. View Article : Google Scholar : PubMed/NCBI
51	Williams R and Gibbons R: Inhibition of bacterial adherence by secretory immunoglobulin A: a mechanism of antigen disposal. Science. 177:697–699. 1972. View Article : Google Scholar : PubMed/NCBI
52	Tjärnlund A, Rodríguez A, Cardona PJ, et al: Polymeric IgR knockout mice are more susceptible to mycobacterial infections in the respiratory tract than wild-type mice. Int Immunol. 18:807–816. 2006. View Article : Google Scholar : PubMed/NCBI
53	Olivares N, Marquina B, Mata-Espinoza D, et al: The protective effect of immunoglobulin in murine tuberculosis is dependent on IgG glycosylation. Pathog Dis. 69:176–183. 2013. View Article : Google Scholar : PubMed/NCBI
54	Mosmann T and Coffman R: TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 7:145–173. 1989. View Article : Google Scholar : PubMed/NCBI
55	Lamichhane A, Azegamia T and Kiyonoa H: The mucosal immune system for vaccine development. Vaccine. 32:6711–6723. 2014. View Article : Google Scholar : PubMed/NCBI
56	Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH and Hill AV: Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol. 171:1602–1609. 2003. View Article : Google Scholar : PubMed/NCBI
57	Chen L, Wang J, Zganiacz A and Xing Z: Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect Immun. 72:238–246. 2004. View Article : Google Scholar :
58	Santosuosso M, McCormick S, Zhang X, Zganiacz A and Xing Z: Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis. Infect Immun. 74:4634–4643. 2006. View Article : Google Scholar : PubMed/NCBI
59	Yu F, Wang J, Dou J, et al: Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection. Nanomedicine. 8:1337–1344. 2012. View Article : Google Scholar : PubMed/NCBI
60	Ndiaye BP, Thienemann F, Ota M, et al: Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: A randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 3:190–200. 2015. View Article : Google Scholar : PubMed/NCBI
61	Croyle MA, Patel A, Tran KN, et al: Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One. 3:e35482008. View Article : Google Scholar : PubMed/NCBI
62	Lemiale F, Kong WP, Akyurek LM, et al: Enhanced mucosal immunoglobulin A response of intranasal adenoviral vector human immunodeficiency virus vaccine and localization in the central nervous system. J Virol. 77:10078–10087. 2003. View Article : Google Scholar : PubMed/NCBI
63	Richardson JS, Abou MC, Tran KN, Kumar A, Sahai BM and Kobinger GP: Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs. J Infect Dis. 204(Suppl 3): 1032–1042. 2011. View Article : Google Scholar
64	Santosuosso M, Zhang X, McCormick S, Wang J, Hitt M and Xing Z: Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J Immunol. 174:7986–7994. 2005. View Article : Google Scholar : PubMed/NCBI
65	Shim BS, Stadler K, Nguyen HH, et al: Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. Virol J. 9:2152012. View Article : Google Scholar : PubMed/NCBI
66	Kaufman DR, Bivas-Benita M, Simmons NL, Miller D and Barouch DH: Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes. J Virol. 84:5986–5996. 2010. View Article : Google Scholar : PubMed/NCBI